Smithkline Beecham Corporation

Alemseged Truneh

Raymond W Sweet

Shujian Wu

Peter R Young

Mark Robert Hurle

Lisa A Marshall

Amy K Roshak

Keith Charles Deen

Kong B Tan

Kb Tan

John Emery

TR6 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing TR6 polypeptides and polynucleotides in the design of protocols for the treatment of chronic and acute inflammation, arthritis, septicemia, autoimmune diseases (e.g. inflammatory bowel disease, psoriasis), transplant rejection, graft vs. host disease, infection, stroke, ischemia, acute respiratory disease syndrome, restenosis, brain injury, AIDS, Bone diseases, cancer, atheroschlerosis, and Alzheimers disease, among others and diagnostic assays for such conditions.

Tumor necrosis factor related receptor, TR6

PIGR-1 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing PIGR-1 polypeptides and polynucleotides in the design of protocols for the treatment of rheumatoid arthritis (RA), multiple sclerosis (MS), psoriasis, systemic lupus erythematosus (SLE) and inflammatory bowel disease (IBD), among others and diagnostic assays for such conditions.

PIGR-1, a member of immunoglobulin gene superfamily

PIGRL-1 polypeptide and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing PIGRL-1 polypeptide and polynucleotides in the design of protocols for the treatment of Hyper-IgM Immunodeficiency (HIM), X-linked Severe Combined Immunodeficiency (XSCID), and IgA deficiency (IgA-D), among others and diagnostic assays for such conditions.

PIGRL-1, a member of immunoglobulin gene superfamily

HLIG-1 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing HLIG-1 polypeptides and polynucleotides in the design of protocols for the treatment of neurological disorders such as Alzheimer's disease, multiple sclerosis and abnormal neural development; endocrine disorders such as diabetes; and heart disease, among others and diagnostic assays for such conditions.

Human LIG-1 homolog (HLIG-1)

TR4 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing TR4 polypeptides and polynucleotides in the design of protocols for the treatment of chronic and acute inflammation, arthritis, septicemia, autoimmune diseases (eg inflammatory bowel disease, psoriasis), transplant rejection, graft vs. host disease, infection, stroke, ischemia, acute respiratory disease syndrome, restenosis, brain injury, AIDS, Bone diseases, cancer (eg lymphoproliferative disorders), atheroschlerosis, and Alzheimers disease among others, and diagnostic assays for such conditions.

Growing community of inventors

West Chester, PA, United States of America

Alemseged Truneh